|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bertuccio P, Chatenoud L, Levi F, Praud D,
Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent patterns in
gastric cancer: A global overview. Int J Cancer. 125:666–673.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH,
Guo G, Chen W, Liu XF, Zhang JY, Liu T, et al: Increased
intratumoral IL-22-producing CD4+T cells and Th22 cells correlate
with gastric cancer progression and predict poor patient survival.
Cancer Immunol Immunother. 61:1965–1975. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sastre J, Garcia-Saenz JA and Diaz-Rubio
E: Chemotherapy for gastric cancer. World J Gastroenterol.
12:204–213. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ge L, Hou L, Yang Q, Wu Y, Shi X, Li J and
Yang K: A systematic review and network meta-analysis protocol of
adjuvant chemotherapy regimens for resected gastric cancer.
Medicine (Baltimore). 98(e14478)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Janunger KG, Hafström L and Glimelius B:
Chemotherapy in gastric cancer: A review and updated meta-analysis.
Eur J Surg. 168:597–608. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ma J, Shen H, Kapesa L and Zeng S: Lauren
classification and individualized chemotherapy in gastric cancer.
Oncol Lett. 11:2959–2964. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nishina T, Boku N, Gotoh M, Shimada Y,
Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, et
al: Randomized phase II study of second-line chemotherapy with the
best available 5-fluorouracil regimen versus weekly administration
of paclitaxel in far advanced gastric cancer with severe peritoneal
metastases refractory to 5-fluorouracil-containing regimens
(JCOG0407). Gastric Cancer. 19:902–910. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sugarbaker PH: Twenty-year survival of
gastric cancer with peritoneal metastases using long-term
normothermic intraperitoneal 5-fluorouracil and systemic mitomycin
C: A case report. Int J Surg Case Rep. 61:302–304. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ajani J, Abramov M, Bondarenko I, Shparyk
Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu
J, et al: A phase III trial comparing oral S-1/cisplatin and
intravenous 5-fluorouracil/cisplatin in patients with untreated
diffuse gastric cancer. Ann Oncol. 28:2142–2148. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sun L, Yu J, Wang P, Shen M and Ruan S:
HIT000218960 promotes gastric cancer cell proliferation and
migration through upregulation of HMGA2 expression. Oncol Lett.
17:4957–4963. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li T, Yang XD, Ye CX, Shen ZL, Yang Y,
Wang B, Guo P, Gao ZD, Ye YJ, Jiang KW and Wang S: Long noncoding
RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and
tumor progression by upregulating the expression of high mobility
group AT-hook 2 (HMGA2) gene. Cell Cycle. 16:224–231.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Edge SB, Byrd DR, Compton CC (eds.), et
al: Stomach. In: AJCC Cancer Staging Manual. 7th edition. Springer,
New York, NY, pp117-126, 2010.
|
|
14
|
Kusaba H and Saijo N: A summary report of
response evaluation criteria in solid tumors (RECIST criteria). Gan
To Kagaku Ryoho. 27:1–5. 2000.PubMed/NCBI(In Japanese).
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta c(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang L, Wang H, Xu J, Zhu J and Ding K:
Inhibition of cathepsin S induces autophagy and apoptosis in human
glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K
and JNK signaling pathways. Toxicol Lett. 228:248–259.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ladu S, Calvisi DF, Conner EA, Factor VM
and Thorgeirsson SS: Co-expression of c-Myc and E2F1 in a mouse
model of liver cancer suppresses apoptosis through activation of
Akt/mTOR/p70S6K and COX-2 pathways: Relevance for human
hepatocellular carcinoma. Cancer Res,. 65
(9_Supplement)(258)2005.
|
|
18
|
Yu KR, Park SB, Jung JW, Seo MS, Hong IS,
Kim HS, Seo Y, Kang TW, Lee JY, Kurtz A and Kang KS: HMGA2
regulates the in vitro aging and proliferation of human umbilical
cord blood-derived stromal cells through the mTOR/p70S6K signaling
pathway. Stem Cell Res. 10:156–165. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yi Z, Hui L, Fang S, Kang Y, Wu W, Hao Y,
Li Z, Bu D, Sun N, Zhang MQ and Chen R: NONCODE 2016: An
informative and valuable data source of long non-coding RNAs.
Nucleic Acids Res. 44(D1):D203–D208. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ulitsky I: Evolution to the rescue: Using
comparative genomics to understand long non-coding RNAs. Nat Rev
Genet. 17:601–614. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Boon RA, Jaé N, Holdt L and Dimmeler S:
Long Noncoding RNAs: From clinical genetics to therapeutic targets?
J Am Coll Cardiol. 67:1214–1226. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Wang HM, Lu JH, Chen WY and Gu AQ:
Upregulated lncRNA-UCA1 contributes to progression of lung cancer
and is closely related to clinical diagnosis as a predictive
biomarker in plasma. Int J Clin Exp Med. 8:11824–11830.
2015.PubMed/NCBI
|
|
24
|
Tang D, Zhao L, Peng C, Ran K, Mu R and Ao
Y: LncRNA CRNDE promotes hepatocellular carcinoma progression by
upregulating SIX1 through modulating miR7. J Cell Biochem.
120:16128–16142. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kondo Y, Shinjo K and Katsushima K: Long
non-coding RNAs as an epigenetic regulator in human cancers. Cancer
Sci. 108:1927–1933. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shen XH, Qi P and Du X: Long non-coding
RNAs in cancer invasion and metastasis. Mod Pathol. 28:4–13.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y,
Zhang F, Lu Y, Zheng L, Zhang W and Li X and Li X: Long non-coding
RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin
pathway to promote growth and metastasis in colorectal cancer.
Cancer Lett. 376:62–73. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nie D, Zhang L, Guo Q and Mao X: High
mobility group protein A2 overexpression indicates poor prognosis
for cancer patients: A meta-analysis. Oncotarget. 9:1237–1247.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Summer H, Li O, Bao Q, Zhan L, Peter S,
Sathiyanathan P, Henderson D, Klonisch T, Goodman SD and Dröge P:
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer
cells from DNA-damage-induced cytotoxicity during chemotherapy.
Nucleic Acids Res. 37:4371–4384. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dangi-Garimella S, Sahai V, Ebine K, Kumar
K and Munshi HG: Three-dimensional collagen I promotes gemcitabine
resistance in vitro in pancreatic cancer cells through
HMGA2-Dependent histone acetyltransferase expression. PLoS One.
8(e64566)2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhu J, Wang H, Xu S and Hao Y:
Clinicopathological and prognostic significance of HMGA2
overexpression in gastric cancer: A meta-analysis. Oncotarget.
8:100478–100489. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Jun KH, Jung JH, Choi HJ, Shin EY and Chin
HM: HMGA1/HMGA2 protein expression and prognostic implications in
gastric cancer. Int J Surg. 24(Pt A):39–44. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang H, Jiang Z, Chen H, Wu X, Xiang J and
Peng J: MicroRNA-495 inhibits gastric cancer cell migration and
invasion possibly via targeting high mobility group AT-Hook 2
(HMGA2). Med Sci Monit. 23:640–648. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yang X, Zhao Q, Yin H, Lei X and Gan R:
MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs
via inhibiting HMGA2 expression. J Drug Target. 25:653–660.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene.
22:8983–8998. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tsuruta F, Masuyama N and Gotoh Y: The
Phosphatidylinositol 3-Kinase (PI3K)-Akt Pathway Suppresses Bax
Translocation to Mitochondria. J Biol Chem. 277:14040–14047.
2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhu L, Derijard B, Chakrabandhu K, Wang
BS, Chen HZ and Hueber AO: Synergism of PI3K/Akt inhibition and Fas
activation on colon cancer cell death. Cancer Lett. 354:355–364.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Iyer AK, Azad N, Talbot S, Stehlik C, Lu
B, Wang L and Rojanasakul Y: Antioxidant c-FLIP inhibits Fas
ligand-induced NF-kappaB activation in a phosphatidylinositol
3-Kinase/Akt-dependent manner. J Immunol. 187:3256–3266.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhao P, Meng Q, Liu L-Z, You Y-P, Liu N
and Jiang B-H: Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Biochem Biophys Res Commun. 395:219–224. 2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Chai X, Sun D, Han Q, Yi L, Wu Y and Liu
X: Hypoxia induces pulmonary arterial fibroblast proliferation,
migration, differentiation and vascular remodeling via the
PI3K/Akt/p70S6K signaling pathway. Int J Mol Med. 41:2461–2472.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mo J, Li B, Zhou Y, Xu Y, Jiang H, Cheng
X, Wu X and Zhang Y: LINC00473 promotes hepatocellular carcinoma
progression via acting as a ceRNA for microRNA-195 and increasing
HMGA2 expression. Biomed Pharmacother. 120(109403)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dong K, Bai L, Tong D, Shi X, Wei S and
Cai Y: Long non-coding RNA HIT000218960 is associated with poor
prognosis in patients with gastric cancer. Exp Ther Med.
22(694)2021.PubMed/NCBI View Article : Google Scholar
|
